Compare HubSpot Inc (HUBS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? HubSpot Inc trades at $223.77 (market cap $11.03B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: HubSpot Inc is far larger — about 11.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HUBS | MRVI | |
|---|---|---|
Market Cap | $11.03B | $972.90M |
Volume | 784,639 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $494.58 | $9.00 |
52-Week Low | $170.39 | $2.83 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $9.93B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $226.23, up 1.28% today, with a neutral technical signal and strong fundamental growth. The stock has beaten earnings estimates for the last three quarters, with revenue growing from $1.7B in 2022 to $3.1B in 2025. Recent news highlights an AI-focused strategy and partnership with OpenAI, aiming to boost margins and customer outcomes.
The outlook is positive with 55% analyst buy ratings and a $244.09 consensus price target, suggesting 8% upside. Key risks include high valuation multiples and competitive pressures in the SaaS space. Cash flow growth and institutional accumulation support the bullish case, but investors should monitor execution of AI initiatives and margin targets.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
